TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33042569

Group type: EXPERIMENTAL
Intervention: Tailored lifestyle intervention delivered by peer coaches via 3 core home visits every 4-6 weeks and additional support via text.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tailored lifestyle intervention delivered by peer coaches.
Number of subjects: 100
Study: 33042571

Group type: EXPERIMENTAL
Intervention: 9-week Goal Management Training (GMT) program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both groups (active and control)
Number of subjects: 19
Study: 33042579

Group type: EXPERIMENTAL
Intervention: IV infusions of 4 mg/kg tocilizumab (TCZ)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: IV infusions of 8 mg/kg tocilizumab (TCZ)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment)
Number of subjects: 37
Study: 33042916

Group type: EXPERIMENTAL
Intervention: Solvent/Detergent-Treated Plasma
Number of subjects: 0
Study: 33042935

Group type: EXPERIMENTAL
Intervention: Intervention to reduce excessive drinking, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33043164

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, up to 800 mg, single shot)
Number of subjects: 0
Study: 33043304

Group type: EXPERIMENTAL
Intervention: 3 to 4 cycles of BEP chemotherapy (high-intensity cisplatin)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intra-arterial bradykinin, acetylcholine, and sodium nitroprusside
Number of subjects: 53
Study: 33043735

Group type: EXPERIMENTAL
Intervention: Tosedostat
Number of subjects: 0
Study: 33044119

Group type: EXPERIMENTAL
Intervention: Viabahn endoprosthesis with Propaten bioactive surface
Number of subjects: 0
Study: 33044494

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 3074

Group type: EXPERIMENTAL
Intervention: Standard treatment group
Number of subjects: 3074

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 3074
Study: 33044566

Group type: EXPERIMENTAL
Intervention: Ensartinib (200 mg/100 μCi)
Number of subjects: 6
Study: 33044747

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 38160
Study: 33045006

Group type: EXPERIMENTAL
Intervention: Ionized calcium level
Number of subjects: 883

Group type: COMPARATOR
Intervention: Calcium level
Number of subjects: 883
Study: 33045104

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 478
Study: 33045316

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wP) at 80 mg/m² for 6 weeks + Low-dose fractionated whole abdominal radiation therapy (LDFWART)
Number of subjects: 10
Study: 33045380

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 0
Study: 33045409

Group type: EXPERIMENTAL
Intervention: Pre-stage-2 SVHD infants
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study: 33045496

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600-mg Dose 2 or 3 infused over approximately 2 hours (Cohort 1)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 300-mg Dose 1, Infusion 2 over approximately 1.5 hours (Cohort 2)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (both cohorts)
Number of subjects: 141
Study: 33045664

Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal therapy (LITT)
Number of subjects: 60
Study: 33045668

Group type: EXPERIMENTAL
Intervention: ≥4 lifestyle risk factors
Number of subjects: 535

Group type: COMPARATOR
Intervention: Zero or one risk factor
Number of subjects: 535

Group type: COMPARATOR
Intervention: Two risk factors
Number of subjects: 535

Group type: COMPARATOR
Intervention: Three risk factors
Number of subjects: 535

Group type: COMPARATOR
Intervention: Four risk factors
Number of subjects: 535

Group type: COMPARATOR
Intervention: ≥5 risk factors
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Lifestyle habits (six factors)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Postpartum depression
Number of subjects: 535
Study: 33045994

Group type: EXPERIMENTAL
Intervention: Shifts from low/high to middle category (L-M/H-M) for phosphorus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shifts from middle to low/high category (M-L/M-H) for phosphorus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shifts from low/middle to high category (L-H/M-H) for calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shifts from high to middle category (H-M) for calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shifts from low to middle category (L-M) for intact parathyroid hormone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in 3-month patterns of phosphorus and calcium toward the middle category
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoiding hypercalcemia
Number of subjects: 0
Study: 33046003

Group type: EXPERIMENTAL
Intervention: Unintended pregnancies
Number of subjects: 870
Study: 33046066

Group type: EXPERIMENTAL
Intervention: ART with frequent viral load testing until achieving undetectable viral load (ART-VL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: daily oral pre-exposure prophylaxis (PrEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: semen-washing with intrauterine insemination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: manual self-insemination at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ART-VL plus PrEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current HIV clinical practices
Number of subjects: 0
Study: 33046203

Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus (DM)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Patients without diabetes mellitus (DM)
Number of subjects: 235
Study: 33046437

Group type: EXPERIMENTAL
Intervention: Cardioband tricuspid valve reconstruction system
Number of subjects: 30
Study: 33046513

Group type: EXPERIMENTAL
Intervention: Single intratumoral injection
Number of subjects: 24
Study: 33046516

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus osimertinib
Number of subjects: 25
Study: 33046518

Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226) administered intravenously at a dosage of 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226)
Number of subjects: 37
Study: 33046517

Group type: EXPERIMENTAL
Intervention: CC-90011 at 60 mg once per week (RP2D)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CC-90011 at 120 mg once per week (NTD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CC-90011 at 80 mg once per week (MTD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CC-90011
Number of subjects: 50
Study: 33046573

Group type: EXPERIMENTAL
Intervention: Molecular-integrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard adjuvant vaginal brachytherapy
Number of subjects: 500
Study: 33046621

Group type: EXPERIMENTAL
Intervention: AMG 820 (1100 mg or 1400 mg) plus pembrolizumab (200 mg) intravenously every 3 weeks
Number of subjects: 116
Study: 33046765

Group type: EXPERIMENTAL
Intervention: Antihypertensive medications with a reduction in hsCRP levels of 40% or greater (responder group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertensive medications with a reduction in hsCRP levels of less than 40% (non-responder group)
Number of subjects: 0
Study: 33046861

Group type: EXPERIMENTAL
Intervention: Data-driven computational model of similarity judgements for real-world images of objects
Number of subjects: 1854

Group type: EXPERIMENTAL
Intervention: Data-driven computational model
Number of subjects: 1854

Group type: EXPERIMENTAL
Intervention: Human similarity judgements
Number of subjects: 1854
Study: 33046868

Group type: EXPERIMENTAL
Intervention: Autologous NKT cells engineered to co-express a GD2-specific chimeric antigen receptor (CAR) with interleukin-15
Number of subjects: 3
Study: 33046870

Group type: EXPERIMENTAL
Intervention: Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies
Number of subjects: 0
Study: 33046998

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparin, dosage based on weight, D-dimer levels, and clinical condition.
Number of subjects: 80
Study: 33047248

Group type: EXPERIMENTAL
Intervention: IntraOmmaya antiGD2 monoclonal antibody
Number of subjects: 61
Study: 33047298

Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant topical corticosteroids
Number of subjects: 740
Study: 33047329

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Dose adjustments to 40 mg/day for IM patients and 80 mg/day for PM patients
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Dose increase to 60 mg/day for PM patients
Number of subjects: 928
Study: 33047430

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 113
Study: 33047438

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 0
Study: 33047583

Group type: EXPERIMENTAL
Intervention: Neutrophil CD64 index (iCD64n) measured on postoperative days 3 and 6
Number of subjects: 73
Study: 33047816

Group type: EXPERIMENTAL
Intervention: High-volume evacuator (HVE)
Number of subjects: 425

Group type: COMPARATOR
Intervention: High-volume evacuator (HVE) vs. conventional dental suction
Number of subjects: 425

Group type: COMPARATOR
Intervention: Dental isolation combination system (Isolite)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Rubber dam plus HVE
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Local stand-alone air cleaning system (ACS)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Laminar flow with HEPA filter
Number of subjects: 425

Group type: COMPARATOR
Intervention: Antimicrobial coolants (chlorhexidine, povidone iodine, cinnamon extract)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Chlorhexidine coolant
Number of subjects: 425
Study: 33048057

Group type: EXPERIMENTAL
Intervention: Remote titration facilitated by telemonitoring using a smartphone-based system
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard titration program consisting of in-office visits
Number of subjects: 76
Study: 33048203

Group type: EXPERIMENTAL
Intervention: Ravulizumab (loading dose on Day 1, maintenance doses every 4-8 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 10
Study: 33048619

Group type: EXPERIMENTAL
Intervention: Targeted therapy antitumor activity in underexplored cancer types (specific treatments not detailed)
Number of subjects: 5954
Study: 33048900

Group type: EXPERIMENTAL
Intervention: Augmented renal clearance predictor
Number of subjects: 10259

Group type: COMPARATOR
Intervention: Existing models for augmented renal clearance
Number of subjects: 10259
Study: 33049057

Group type: EXPERIMENTAL
Intervention: TN-depleted peripheral blood stem cell (PBSC) grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard unselected HCT
Number of subjects: 0
Study: 33049248

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33049644

Group type: EXPERIMENTAL
Intervention: ICD-11 PGD criteria
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Expanded supplementary questionnaire of culturally-bound grief symptoms
Number of subjects: 539

Group type: COMPARATOR
Intervention: Standard PGD network
Number of subjects: 539
Study: 33050261

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 33050459

Group type: EXPERIMENTAL
Intervention: Mangafodipir or other SOD mimetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33050804

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) - sunitinib, pazopanib, sorafenib
Number of subjects: 151
Study: 33050890

Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Participants with JIA using synthetic and biologic DMARDs
Number of subjects: 221
Study: 33051036

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) for 6 months
Number of subjects: 101
Study: 33051234

Group type: EXPERIMENTAL
Intervention: Weekly community dance sessions designed for people with breathlessness, lasting 75 min, led by a trained community dance leader.
Number of subjects: 8
Study: 33051264

Group type: EXPERIMENTAL
Intervention: Belimumab plus standard therapy
Number of subjects: 362

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 362
Study: 33051459

Group type: EXPERIMENTAL
Intervention: Short-term leptin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term leptin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 0
Study: 33051668

Group type: EXPERIMENTAL
Intervention: Darinaparsin 200 mg/m2/day in 4-week cycles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Darinaparsin 300 mg/m2/day in 4-week cycles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Darinaparsin 300 mg/m2/day in 3-week cycles
Number of subjects: 23
Study: 33051855

Group type: EXPERIMENTAL
Intervention: Montreal museum of fine arts (MMFA) participatory art-based activities, one weekly structured workshop over a 3-month period.
Number of subjects: 101
Study: 33052476

Group type: EXPERIMENTAL
Intervention: Standardized swallowing test performed 24 hours after extubation
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Second swallowing test performed 48 hours after the first test
Number of subjects: 138

Group type: COMPARATOR
Intervention: Comparison of characteristics between patients with persistent SD and those without or with transient SD
Number of subjects: 138

Group type: COMPARATOR
Intervention: Duration of ICU stay after first extubation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Delay to oral feeding
Number of subjects: 138
Study: 33052556

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg plus gefitinib 250 mg orally once daily
Number of subjects: 64
Study: 33052718

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33052753

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33053154

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in PX patients
Number of subjects: 10
Study: 33053284

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Usual obesity care (control group)
Number of subjects: 2007
Study: 33053612

Group type: COMPARATOR
Intervention: Oil-soluble contrast media (OSCM)
Number of subjects: 3864

Group type: COMPARATOR
Intervention: Water-soluble contrast media (WSCM)
Number of subjects: 3864
Study: 33054054

Group type: EXPERIMENTAL
Intervention: BCL2 alterations
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: BCL2 gene and protein expression levels
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Mutational subsets
Number of subjects: 499
Study: 33054084

Group type: EXPERIMENTAL
Intervention: Ofatumumab-CHL (O-CHL)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Chlorambucil (CHL)
Number of subjects: 383
Study: 33054114

Group type: EXPERIMENTAL
Intervention: Pediatric-inspired chemotherapy incorporating 6 doses of pegaspargase 2000 IU/m2
Number of subjects: 39
Study: 33054130

Group type: COMPARATOR
Intervention: CC variant
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TT variant
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both variants
Number of subjects: 79
Study: 33054753

Group type: EXPERIMENTAL
Intervention: Family Move app-based intervention (parent-child exercises)
Number of subjects: 67
Study: 33054845

Group type: EXPERIMENTAL
Intervention: Educational intervention combining clinical obesity preceptorship and electronic networking tools
Number of subjects: 35
Study: 33054971

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33055233

Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcer prevention program with once-daily foot temperature monitoring
Number of subjects: 80
Study: 33055274

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Non-aspirin group
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1866
Study: 33057585

Group type: EXPERIMENTAL
Intervention: E-nside off-the-shelf multibranched endograft
Number of subjects: 268
Study: 33057634

Group type: EXPERIMENTAL
Intervention: D-dimer testing followed by whole-leg compression ultrasonography (CUS) for patients with positive D-dimer (≥0.5 µg/mL)
Number of subjects: 1397
Study: 33057657

Group type: EXPERIMENTAL
Intervention: TAVR with none-to-trace PVR
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: TAVR with mild PVR
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: TAVR with moderate-to-severe PVR
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: SAVR with none-to-trace PVR
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: SAVR with mild PVR
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: SAVR with moderate-to-severe PVR
Number of subjects: 6463

Group type: COMPARATOR
Intervention: TAVR
Number of subjects: 6463

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 6463
Study: 33057725

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID or 10 mg BID
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Tofacitinib (monotherapy or with csDMARDs)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Tofacitinib (exploratory analysis)
Number of subjects: 414
Study: 33057928

Group type: EXPERIMENTAL
Intervention: Anatomic imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Other imaging modalities
Number of subjects: 50
Study: 33058137

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 10812
Study: 33058182

Group type: EXPERIMENTAL
Intervention: Surgical therapy (n=86)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Medical therapy (n=68)
Number of subjects: 154
Study: 33058232

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 33058496

Group type: EXPERIMENTAL
Intervention: Plasma cystatin C monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary cystatin C/creatinine ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radionucleide glomerular exploration
Number of subjects: 0
Study: 33058695

Group type: EXPERIMENTAL
Intervention: Baseline GDF-15 concentrations
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: GDF-15 prognostic value
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Primary end point (admission to ICU or death)
Number of subjects: 123
Study: 33059200

Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention, a community-engaged, data-driven planning process.
Number of subjects: 67
Study: 33059645

Group type: EXPERIMENTAL
Intervention: Periodontitis (PT)
Number of subjects: 101
Study: 33059715

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33059838

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33060077

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks for three cycles)
Number of subjects: 0
Study: 33060149

Group type: EXPERIMENTAL
Intervention: HX008 200 mg intravenously every 3 weeks plus irinotecan 160 mg/m²
Number of subjects: 58
Study: 33060153

Group type: EXPERIMENTAL
Intervention: RSV illness (PCR-confirmed ARTI)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: RSV ARTI (PCR confirmed)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: RSV illness
Number of subjects: 1040
Study: 33060506

Group type: EXPERIMENTAL
Intervention: Acute kidney injury stage 1
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Acute kidney injury stage 2
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Acute kidney injury stage 3
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Renal history
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Hypernatremia
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Osmotic therapy administration
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 1262
Study: 33060529

Group type: EXPERIMENTAL
Intervention: Thin-strut cobalt chromium sirolimus-eluting stent (SES, Ultimaster)
Number of subjects: 10875

Group type: COMPARATOR
Intervention: Thicker strut stainless steel biolimus-eluting stent (BES, Nobori)
Number of subjects: 10875
Study: 33061274

Group type: EXPERIMENTAL
Intervention: First cataract surgery (group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Second cataract surgery (group II)
Number of subjects: 200
Study: 33061276

Group type: EXPERIMENTAL
Intervention: +3.25 D Tecnis IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +4.00 D Tecnis IOL
Number of subjects: 0
Study: 33061341

Group type: EXPERIMENTAL
Intervention: COPD patients during COVID-19 pandemic
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with pre-existing COPD
Number of subjects: 489

Group type: COMPARATOR
Intervention: COPD patients compared to previous year
Number of subjects: 489
Study: 33061347

Group type: EXPERIMENTAL
Intervention: Unsupervised Home-Based Pulmonary Rehabilitation (HBPR)
Number of subjects: 41
Study: 33061494

Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet+NB group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mediterranean diet alone (breast cancer survivor MeDiet-only group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group)
Number of subjects: 72
Study: 33061500

Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 33061515

Group type: EXPERIMENTAL
Intervention: Right-lateral starting position (RLP)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Left-lateral starting position (LLP)
Number of subjects: 142
Study: 33062061

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 13
Study: 33062063

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 131

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 131